Menu
Back to Journals » Core Evidence » Volume 6
ESCI
Core Evidence
- View all (140)
- Volume 15, 2020 (1)
- Volume 14, 2019 (6)
- Volume 13, 2018 (3)
- Volume 12, 2017 (2)
- Volume 11, 2016 (5)
- Volume 10, 2015 (9)
- Volume 9, 2014 (13)
- Volume 8, 2013 (7)
- Volume 7, 2012 (12)
- Volume 6, 2011 (7)
- Volume 5, 2010 (9)
- Volume 4, 2009 (20)
- Volume 3, 2008 (5)
- Volume 2, 2007 (22)
- Volume 1-Issues 3 & 4, 2006 (8)
- Volume 1-Issues 1 & 2, 2005 (11)
Archive: Volume 6, 2011
Review
Lixisenatide: evidence for its potential use in the treatment of type 2 diabetes
Barnett AH
Core Evidence 2011, 6:67-79
Published Date: 8 September 2011
Review
Aztreonam (for inhalation solution) for the treatment of chronic lung infections in patients with cystic fibrosis: an evidence-based review
Kirkby S, Novak K, McCoy K
Core Evidence 2011, 6:59-66
Published Date: 11 August 2011
Review
Emerging role of carfilzomib in treatment of relapsed and refractory lymphoid neoplasms and multiple myeloma
Jain S, Diefenbach C, Zain J, O'Connor OA
Core Evidence 2011, 6:43-57
Published Date: 4 April 2011
Review
Ticagrelor: the evidence for its clinical potential as an oral antiplatelet treatment for the reduction of major adverse cardiac events in patients with acute coronary syndromes
Bernardo Lombo, José G Díez
Core Evidence 2011, 6:31-42
Published Date: 17 March 2011
Review
Plerixafor for autologous CD34+ cell mobilization
Huda Salman, Hillard M Lazarus
Core Evidence 2011, 6:23-29
Published Date: 8 February 2011
Review
Evidence-based assessment of potential use of fingolimod in treatment of relapsing multiple sclerosis
Emilio Portaccio
Core Evidence 2011, 6:13-21
Published Date: 6 January 2011
Review
Romidepsin: evidence for its potential use to manage previously treated cutaneous T cell lymphoma
Brian Poligone, Janet Lin, Catherine Chung
Core Evidence 2011, 6:1-12
Published Date: 22 December 2010